MedTrace Logo

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-02-10

No results posted yet for this study

Summary

This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas

Conditions

Interventions

BIOLOGICAL

Biological G207

Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI

Sponsors & Collaborators

  • Treovir, LLC

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • American Lebanese Syrian Associated Charities

    collaborator OTHER

  • Pediatric Brain Tumor Consortium

    lead NETWORK

Principal Investigators

  • Gregory Friedman, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2025-12-18
Completion
2025-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482933 on ClinicalTrials.gov